SRTAHealthcare · Medical Care FacilitiesThe 4 Wall Street analysts covering Strata Critical Medical, Inc. hold a median 12-month price target of $8.75 — +67.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 4 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Strata Critical Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (75): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (29): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SRTA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +67.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Mar 2026 | B. Riley Securities | Initiates | Buy | $8.00 |
| 25 Mar 2026 | B. Riley Securities | Initiates | Buy | — |
| 25 Mar 2026 | Craig-Hallum | Initiates | Buy | $8.00 |
| 25 Mar 2026 | Craig-Hallum | Initiates | Buy | — |
| 2 Dec 2025 | Lake Street | Assumes | Buy | $8.00 |
| 17 Sept 2025 | Lake Street | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SRTA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Strata Critical Medical, Inc. returned +10.8% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 55% of US stocks
Cheaper than 56% of US stocks
Cheaper than 50% of US stocks
Cheaper than 8% of US stocks
Higher than 86% of US stocks
Higher than 40% of US stocks
Higher than 22% of US stocks
Higher than 27% of US stocks
Higher than 20% of US stocks
Higher than 37% of US stocks
Higher than 38% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Strata Critical Medical, Inc. has a market value of $467.0M and an enterprise value of $358.6M.
Revenue in the twelve months to 30 June 2026: $256.0M. The latest quarter grew 50.3% year on year.
Net income over the same four quarters: $40.2M, a 15.7% net margin.
Diluted earnings per share, trailing twelve months: $0.51.
Free cash flow in the twelve months to 30 June 2026: −$49.5M, after $1.1M of capital spending.
Trailing P/E: 11.0×; forward P/E: 1570.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Strata Critical Medical, Inc. employs 327 people — $783K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Strata Critical Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Strata Critical Medical announced that management will present at the UBS Global Healthcare Conference on November 10, 2026, at 12:30 p.m. ET. A webcast will be available.
Why it matters — SRTA watchers may note the scheduled opportunity to hear from company management at the healthcare conference.
Seeking Alpha published a transcript of Strata Critical Medical, Inc.’s Q3 2026 earnings call; the provided text contains no further call details.
Why it matters — The transcript is a source for SRTA watchers seeking information about the company’s quarterly call, but no specific financial or operating updates are included in the excerpt.
Strata Critical Medical reported fiscal third-quarter 2026 revenue growth of 50.3% year over year, higher adjusted EBITDA, improved logistics margins, and record free cash flow. The company also expanded its integrated transplant-services platform.
Why it matters — The reported growth and operating improvements provide SRTA watchers with an update on the company’s financial performance and platform expansion.
Strata Critical Medical reported Q3 2026 revenue of $74.1 million, up 50.3% year over year, and a net loss from continuing operations of $7.6 million. Adjusted EBITDA was $9.6 million, operating cash flow was $9.5 million, and the company announced a $20 million share repurchase authorization alongside its continued M&A strategy.
Why it matters — The results highlight revenue growth, a continuing-operations net loss, cash generation, and planned capital deployment through repurchases and acquisitions.
Strata Critical Medical said it will release third-quarter 2026 financial results before the market opens on November 3, 2026, and hold a conference call at 8:00 a.m. Eastern Time that day. Co-CEOs Melissa Tomkiel and Will Heyburn will host the call, which will include a question-and-answer session.
Why it matters — The announcement gives SRTA watchers the timing and format for the company’s quarterly results discussion.
The 4 Wall Street analysts covering Strata Critical Medical, Inc. have a median 12-month price target of $8.75, with estimates ranging from $8 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Strata Critical Medical, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Strata Critical Medical, Inc. 52 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Strata Critical Medical, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (75 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +67.4% from the last close, and Ticker Nerd's factor model ranks Strata Critical Medical, Inc. 52 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Strata Critical Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SRTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $13 over the next 12 months.
Strata Critical Medical, Inc. returned +10.8% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States.
The most recent item we track (GlobeNewsWire, 3 Nov 2026): "Strata Critical Medical to Present at the UBS Global Healthcare Conference". Strata Critical Medical announced that management will present at the UBS Global Healthcare Conference on November 10, 2026, at 12:30 p.m. ET. A webcast will be available.
Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States. It operates in two segments, Logistics and Clinical. The company offers logistics services, such as air and ground transportation for human organs, transplant teams, and related medical materials and organ placement services; transplant clinical services, including organ recovery procedures, normothermic regional perfusion, and preservation services. It also provides other clinical services comprising cardiac perfusion services, blood management and autotransfusion services, extracorporeal membrane oxygenation services, perfusion staffing, and equipment rentals. The company was formerly known as Blade Air Mobility, Inc. and changed its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.
CEO Ms. Melissa M. Tomkiel J.D. · 327 employees · United States · https://www.stratacritical.com
